Haemonetics
292 hedge funds and large institutions have $5.92B invested in Haemonetics in 2018 Q3 according to their latest regulatory filings, with 51 funds opening new positions, 71 increasing their positions, 146 reducing their positions, and 49 closing their positions.
31% more capital invested
Capital invested by funds: $4.52B → $5.92B (+$1.41B)
3.58% more ownership
Funds ownership: 96.47% → 100.06% (+3.6%)
4% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 49
0% less funds holding
Funds holding: 293 → 292 (-1)
21% less call options, than puts
Call options by funds: $3.42M | Put options by funds: $4.35M
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
51% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 146
Top Buyers
Top Sellers
HAE Hedge Fund Activity: Q3 2018 in Review
292 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q3 2018, worth a combined $5.92B — up 31% from $4.52B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new HAE positions and 49 closed out — a net gain of 2 holders — while 71 added to existing stakes and 146 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $267M. The largest seller was Nitorum Capital, cutting an estimated $41.2M.
- 292 institutional investors held Haemonetics (HAE) as of Q3 2018, down from 293 in Q2 2018.
- Funds reported $5.92B of Haemonetics stock for Q3 2018, up 31% quarter-over-quarter.
- 51 funds opened new Haemonetics positions in Q3 2018 and 49 closed out, a net change of +2 holders.
- The largest Haemonetics buyer in Q3 2018 was Wellington Management Group, an estimated $267M added.
- The largest Haemonetics seller in Q3 2018 was Nitorum Capital, an estimated $41.2M sold.
Based on aggregated 13F filings for Q3 2018.